Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Androxal: Phase I/II data

In a U.S. Phase I/II trial in 70 patients with testosterone levels <300 ng/dl, Androxal

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE